BERKELEY HEIGHTS, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced that Richard J. Moran, Senior Vice-President and Chief Financial Officer, has indicated his intention to retire from the Company effective February 29, 2008. Upon Mr. Moran's retirement, Gary Siegel, currently Vice President of Finance, will assume the roles of Principal Accounting Officer and Principal Financial Officer. Mr. Siegel has served the Company for the past 5 years in financial roles of increasing responsibility. An executive recruitment firm, Spencer Stuart, has been engaged by Genta to assist in the search for Mr. Moran's successor. Mr. Moran has agreed to serve as a consultant to the Company to ensure a smooth transition during this period.
Genta also announced the appointment of Michael M. Yoshitsu, PhD, an experienced pharmaceutical executive, as Vice President, Global Business Development. In this capacity, Dr. Yoshitsu will lead activities related to in-licensing of new products, as well as partnering negotiations for the Company's existing products, including Genasense(R) (oblimersen sodium) Injection, Ganite(R) (gallium nitrate injection), and G4544, a new oral drug for accelerated bone loss. Mr. Yoshitsu's background appears below.
"On behalf of the Board, I want to thank Dick Moran for his years of outstanding service and contributions during his tenure at Genta," said Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer. "We are also pleased that Dr. Yoshitsu has agreed to join us in leading our key business development activities that are currently active on a number of fronts."
Biographical Sketch of Michael M. Yoshitsu, PhD
Dr. Yoshitsu has more than 20 years of expe
|SOURCE Genta Incorporated|
Copyright©2008 PR Newswire.
All rights reserved